Vedere Bio II Revenue and Competitors
Estimated Revenue & Valuation
- Vedere Bio II's estimated annual revenue is currently $1.4M per year.
- Vedere Bio II's estimated revenue per employee is $155,000
Employee Data
- Vedere Bio II has 9 Employees.
- Vedere Bio II grew their employee count by -79% last year.
Vedere Bio II's People
| Name | Title | Email/Phone |
|---|
Vedere Bio II Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Vedere Bio II?
Vedere® is a stealth-stage company developing best-in-class genotype-agnostic gene therapies for vision restoration.
keywords:N/A
N/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
-79%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vedere Bio II News
2022-04-13 - Vedere Bio II Announces Appointment of Industry Veteran ...
Vedere Bio II Announces Appointment of Industry Veteran Gina Consylman as Chief Financial Officer. (PRNewsfoto/Vedere Bio, Inc.) News provided...
2022-04-13 - Movers & Shakers, April 15: Spruce, Nautilus, Alto, Ikena ...
Prior to AskBio, Mansell was managing director and founder of White Oak BioPharma ... Vedere Bio II: Gina Consylman was named CFO of Vedere.
2022-04-06 - Belite Bio hits go on IPO to fund late-phase vision loss clinical ...
Belite Bio wants public investors to bankroll late-phase clinical trials of a ... Vedere Bio II has hired Gina Consylman as CFO to chart the financial...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | -10% | N/A |
#4 | $0.7M | 9 | -71% | $138.8M |
#5 | $0.7M | 9 | -25% | N/A |